Organic compounds -- part of the class 532-570 series – Organic compounds – Amino nitrogen containing
Reexamination Certificate
2005-05-17
2005-05-17
Davis, Brain (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Amino nitrogen containing
C564S338000, C564S415000
Reexamination Certificate
active
06894189
ABSTRACT:
This invention encompasses novel methods of preparing sibutramine and sibutramine derivatives, and stereomerically pure sibutramine derivatives in particular. Examples of sibutramine derivatives include, but are not limited to, sibutramine metabolites such as desmethylsibutramine and didesmethylsibutramine. The invention further encompasses novel compounds useful in the synthesis of sibutramine derivatives.
REFERENCES:
patent: 3155669 (1964-11-01), Janssen et al.
patent: 3155670 (1964-11-01), Janssen et al.
patent: 3471515 (1969-10-01), Troxler et al.
patent: 3536809 (1970-10-01), Applezweig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 3960891 (1976-06-01), Malen et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 4522828 (1985-06-01), Jeffery et al.
patent: 4552828 (1985-11-01), Toya et al.
patent: 4746680 (1988-05-01), Jeffery et al.
patent: 4806570 (1989-02-01), Jeffery et al.
patent: 4814352 (1989-03-01), Jeffery et al.
patent: 4816488 (1989-03-01), Rees
patent: 4871774 (1989-10-01), Rees
patent: 4929629 (1990-05-01), Jeffery
patent: 4939175 (1990-07-01), Ukai et al.
patent: 4988814 (1991-01-01), Abou-Gharbia et al.
patent: 5059595 (1991-10-01), Le Grazie
patent: 5068440 (1991-11-01), Jeffery et al.
patent: 5073543 (1991-12-01), Marshall et al.
patent: 5104899 (1992-04-01), Young et al.
patent: 5120548 (1992-06-01), McClelland et al.
patent: 5250534 (1993-10-01), Bell et al.
patent: 5354556 (1994-10-01), Sparks et al.
patent: 5436272 (1995-07-01), Scheinbaum
patent: 5459164 (1995-10-01), Vargas
patent: 5552429 (1996-09-01), Wong et al.
patent: 5591767 (1997-01-01), Mohr et al.
patent: 5639476 (1997-06-01), Oshlack et al.
patent: 5674553 (1997-10-01), Shinoda et al.
patent: 5719283 (1998-02-01), Bell et al.
patent: 5733566 (1998-03-01), Lewis
patent: 5780051 (1998-07-01), Eswara et al.
patent: 5795880 (1998-08-01), Svec et al.
patent: 6046242 (2000-04-01), Emmelmann
patent: 6127363 (2000-10-01), Doherty et al.
patent: 6174925 (2001-01-01), Bailey et al.
patent: 6610887 (2003-08-01), Senanayake et al.
patent: 32 12 682 (1982-10-01), None
patent: 0 035 597 (1981-09-01), None
patent: 0 781 561 (1997-07-01), None
patent: 2098602 (1982-11-01), None
patent: WO 8806444 (1988-09-01), None
patent: WO 9006110 (1990-06-01), None
patent: WO 9400047 (1994-01-01), None
patent: WO 9400114 (1994-01-01), None
patent: WO 9428902 (1994-12-01), None
patent: WO 9520949 (1995-08-01), None
patent: WO 9521615 (1995-08-01), None
patent: WO 9703675 (1997-02-01), None
patent: WO 9720810 (1997-06-01), None
patent: WO 9806722 (1998-02-01), None
patent: WO 9811884 (1998-03-01), None
patent: WO 9813033 (1998-04-01), None
patent: WO 9813034 (1998-04-01), None
patent: WO 0032182 (1998-11-01), None
patent: WO 9933450 (1999-07-01), None
patent: WO 0054765 (2000-09-01), None
patent: WO 0056148 (2000-09-01), None
patent: WO 0056149 (2000-09-01), None
patent: WO 0056150 (2000-09-01), None
patent: WO 0056151 (2000-09-01), None
patent: WO 0056306 (2000-09-01), None
patent: WO 0056309 (2000-09-01), None
patent: WO 0056314 (2000-09-01), None
patent: WO 0056315 (2000-09-01), None
patent: WO 0056318 (2000-09-01), None
patent: WO 0056321 (2000-09-01), None
patent: WO 0056322 (2000-09-01), None
Baldessarini et al.,Life Sciences39: 1765-1777, (1986).
Buckett et al., “BTS 54 524-An Approach to Rapidly Acting Antidepressant,”New Concepts in Depression2: 167-172 (1988).
Bucket et al., “The Pharmacology of Sibutramine Hydrochloride (BTS 54 524), A New Antidepressant which induces Rapid Noradrenergic Down-Regulation”,Prog. Neuro-Psychopharmacol.&Biol. Psychiat. 12: 575-584 (1988).
Buckett et al., “Sibutramine Hydrochloride,”Drugs of the Future13(8): 736-738 (1988).
Butler, D.,Facile Cycloalkylation of Arylacetonitriles in Dimethyl Sulfoxide, J. Org. Chem., 36:1308-1309 (1971).
Cannone, P., et al.,Effet du Benzene Dans la Reaction de Grignard sur les Nitriles, Tetrahedron Lett., 21:155-58 (1980).
Carstensen, J.,Drug Stability: Principles&Practice, 2d. Ed., pp. 379-380, pp. 379-80, Marcel Dekker, NY, NY, (1995).
Castello, R.A., et al.,Discoloration of Tablets Containing Amines and Lactose, Pharm. Sci. 51(2):106-108 (1962).
Cheetham, S.C., et al., [3H]Paroxetine Binding in Rat Frontal Cortex Strongly Correlates with [3H]5-HT Uptake: Effect of Administration of Various Antidepressant Treatments, Neuropharmacology (1993), 32(8), 737-743.
Cliffe et al., (S)-N-tert-Butyl-3-(4-(2-methoxyphenyl)-piperazine-1-yl)-2-phenylpropanamide [(S)-WAY-100135]: A Selective Antagonist at Presynaptic and Postsynaptic 5-HT1AReceptors, Med. Chem., 36:1509-1510 (1993).
Diagnostic and Statistical Manual of Mental Disorders, Fourth Ed., American Psychiatric Association, (1997).
Diagnostic and Statistical Manual of Mental Disorders, 3rd Ed., American Psychiatric Association (1981).
Dreshfield et al.,Enhancement of Fluoxetine-Dependent Increase of Extracellular Serotonin(5-HT)Levels by(−)-Pindolol, an Antagonist at 5-HT1AReceptors, Neurochem. Res., 21(5):557-562 (1996).
Eliel, E.L.,Stereochemistry of Carbon Compounds(McGraw-Hill, NY, 1962).
Evans et al., “Prevelence of Alzheimer's Disease in a Community Population of Older Persons,” J.A.M.A. 262: 2551-2556 (1989).
Fuentes, J.et al., “Comparison of the apparent anti-depressant activity of (−) and (+) tranylpromine in an animal model”,Chemical Abstracts, 85: 7, p. 31, No. 40768t (1976).
Goodman & Gilman, The Pharmacological Basis of Therapeutics, 362-373, 404 (9thed. McGraw-Hill, 1996).
Gray et al.,The Involvement of the Opioidergic System in the Antinociceptiv Mechanism of Action of Antidepressant Compounds, BR.J. Pharmacol., vol. 124, No. 4, (1998) pp 669-674.
Handbook of Pharmaceutical Excipients, 2nded., Wade and Willer eds., pp. 257-259 (1994).
Heal et al.,A Comparison of the Effects on Central 5-HT Function of Sibutramine Hydrochloride and Other Weight-Modifying Agents, BR.J. Pharmacol. (1998), 125(2), 301-308.
Hillver et al., (S)-5-Fluoro-8-hydroxy-2-(dipropylamino)tetralix: A Putative 5-HT1AReceptor Antagonist, J. Med. Chem., 33:1541-44 (1990).
J. Med. Chem., vol. 36, No. 17, 2540 (1993).
Introduction to Pharmaceutical Dosage Forms, 4th ed., Lea & Febiger, Philadelphia (1985).
Jacques et al., “Enantiomers, Racemates and Resolutions,” (Wiley-Interscience, NY, 1981).
Jamali et al.,Journal of Pharmaceutical Sciences, 78: 9: 695-715 (1989).
Jeffery et al.,Synthesis of Sibutramine, A Novel Cyclobutylalkylamine Useful in the Treatment of Obesity, and its Major Human Metabolites, J. Chem. Soc. Perkin. Trans. 1, 2583-2589 (1996).
King et al., “Clinical Pharmacology of Sibutramine Hydrochloride (BTS 54524) A New Antidepressant, in Healthy Volunteers,”Clinical Pharmac. 26: 607-611 (1989).
Kula et al., “Effects of N-Substituted Phenyltetrahydropyridines on Cerebral High-Affinity Synatosomal Uptake of Dopamine and Other Monoamines in Several Mammalian Species,” Life Sciences34(26): 2567-2575, (1984).
Luscombe et al.,The Contribution of Metabolites to the Rapid and Potent Down-Regulation of Rat Cortical β-Adrenoceptors by the Putative Antidepressant Sibutramine Hydrochloride, Neuropharmacology, vol. 28, No. 2, (1989) pp 129-134.
The Merck Manual of Diagnosis and Therapy, ??th Ed., Merck & Co., Inc., Whitehouse Station, NJ, (1999).
Middlemiss et al.,Centrally Active 5-HT Receptor Agonists and Antagonists, Neurosci. and Biobehv. Rev., 16:75-82 (1992).
Moreau et al.,Behavioral Profile of the 5-HT1AReceptor Antagonist(S)-UH-301 in Rodents and Monkeys, Brain Res. Bull., 29;901-04 (1992).
Nakada et al.,An Enantioconvergent Route to(−)-Kainic Acid, Tetrahedron Lett., 38:857-860 (1997).
Physician's Desk Reference® 473-475 (53rded., 1999).
Physician's Desk Reference® 475-476 (53rded., 1999).
Physician's Desk Reference® 764-766 (53rded., 1999).
Physician's Desk Reference® 823-825 (53rded., 1999).
Physician's Desk Reference® 978-979
Han Zhengxu
Krishnamurthy Dhileepkumar
Pflum Derek
Senanayake Chris Hugh
Davis Brain
Jones Day
Sepracor Inc.
LandOfFree
Methods of preparing didesmethylsibutramine and other... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of preparing didesmethylsibutramine and other..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of preparing didesmethylsibutramine and other... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3445334